Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CA7 | P43166 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.54 |
| ▸ | GCK | P35557 | 14/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RARA | P10276 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1426494 | 1.00 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL320646 | 1.00 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2175603 | 0.91 | GCK (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1107633 | 0.91 | GCK (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1107705 | 0.87 | GCK (0.48) | CA1CA2GCKKDM4EGAA | |
| SCHEMBL1042110 | 0.87 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL320803 | 0.87 | GCK (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12774009 | 0.87 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2654383 | 0.87 | GCK (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1107701 | 0.87 | GCK (0.56) | GCKRARARARBGRM5RARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016112863-A1 | N-SUBSTITUTED-3,5-DISUBSTITUTED BENZAMIDE COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | 中国科学院上海药物研究所 | 2016-07-21 | — | — | WO | disclosed |
| US-8450494-B2 | Disubstituted benzamide derivatives as glucokinase (GK) activators | CADILA HEALTHCARE LIMITED (IN) | 2013-05-28 | — | — | US | disclosed |
| US-8236824-B2 | N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-08-07 | — | — | US | disclosed |
| US-20120149704-A1 | DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LIMITED (IN) | 2012-06-14 | — | — | US | disclosed |
| EP-2445908-A1 | DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | Cadila Healthcare Limited (IN) | 2012-05-02 | — | — | EP | disclosed |
| WO-2012007758-A2 | PHARMACEUTICAL FORMULATIONS | ASTRAZENECA AB (SE) | 2012-01-19 | — | — | WO | disclosed |
| US-20110059941-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B] PYRIDINE/PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| WO-2010150280-A1 | DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LIMITED (IN) | 2010-12-29 | — | — | WO | disclosed |
| US-20100210690-A1 | N-(PYRAZOLE-3-YL)-BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-08-19 | — | — | US | disclosed |
| EP-2078000-A1 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS AS GLUCOKINASE (GLK) ACTIVATORS | AstraZeneca AB (SE) | 2009-07-15 | — | — | EP | disclosed |
| EP-2048137-A1 | Benzamide derivatives and their use as glucokinase activating agents. | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008050117-A1 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS AS GLUCOKINASE (GLK) ACTIVATORS | ASTRAZENECA AB (SE) | 2008-05-02 | — | — | WO | disclosed |
| EP-1902052-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| EP-1891069-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B]PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2007007041-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006125958-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4 , 5B] PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210690-A1 | N-(PYRAZOLE-3-YL)-BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | GCKR, HK1, GCK | CA12 4873/4885CA1 4661/4885CA2 2996/4885 |
| US-20120149704-A1 | DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | GCKR, GCK, GK | CA12 3288/4885CA1 3807/4885CA2 783/4885 |
| US-20110059941-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B] PYRIDINE/PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | GCK, PDXK, GCKR | CA12 4523/4885CA1 4220/4885CA2 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.